Thus, we hypothesized that the inhibition of JAK2 could be an effective treatment strategy for these patients, and performed a prospective pilot study with ruxolitinib, a potent and selective JAK1/JAK2 inhibitor, for treatment of patients with relapsed or refractory HL and PMBCL [11]. This evidence concerns the gene JAK2 and Hodgkins lymphoma.